Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Cancer immunotherapy: the ultimate ally in the tumor war

Can immunotherapy cure cancer? Fighting cancer with our own immune system. It sounds promising. At the end of the 1800s, the controversial Dr. Wil…


Engineered immune cells to fight cancer

Our own immune T-cells can be one of the best defense lines against cancer. Walloon biopharmaceutical company Celyad is using an innovative approa…


Damya Laoui at the forefront of cancer immunotherapy

Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 for her…

POPULAR TAGS

Scientists unravel role of glutamine synthetase in the spread of cancer

Written by DS on in the category news with the tags , .


Scientists have discovered an essential mechanism in the spread of cancer. A team led by professor Massimiliano Mazzone (VIB-KU Leuven) and professor Alessandra Castegna (University of Bari) has demonstrated a way to alter the metabolism of macrophages, a particular type of white blood cell often responsible for supporting tumor growth. They found that reducing the glutamine levels of these macrophages changes their behavior: instead of supporting cancer, the macrophages change back into ‘good’ cells and fight the disease. These groundbreaking findings potentially offer new strategies for immunotherapy. The conclusions of the study are published in the leading scientific journal Cell Reports. 

You might also be interested in our white paper on cancer immunotherapy.

Macrophages play a crucial role in our immune systems: these white blood cells attack foreign micro-organisms and remove harmful substances from the body. In doing so, they also infiltrate tumors and fight cancer cells, aiming to stop the progression of the disease. However, some cancer cells survive this initial attack. Those survivors then turn their enemies – the macrophages – into their allies and program them to support tumor growth.

Glutamine synthetase drives metastasis

While the properties of macrophages have already been extensively studied, this alteration of the cells’ metabolism remained puzzling. These research avenues are being explored by Rosa Martín-Pérez, Erika Palmieri and Alessio Menga in the teams of Mazzone (VIB-KU Leuven Center for Cancer Biology) and Castegna (University of Bari).

The study focused on the role of glutamine synthetase (GS), an enzyme crucial to the creation of proteins. The results show that GS is essential to sustaining ‘pro-tumoral’ macrophages. Consequently, the study suggests that blocking GS in those macrophages stimulates glycolysis (the process by which they convert sugar into energy), which in turn normalizes the tumor’s blood vessel growth and reduces metastasis.

Mazzone: “Both in vitro and in vivo, we were surprised to see how changing the metabolism of the macrophages impacted tumor growth. Inhibiting glutamine synthetase led the hijacked cells to return to their original purpose: fighting cancer cells as an essential element of the immune system. What’s more, our results point to the inhibition of GS as a key therapeutic way to skew macrophages towards preventing metastases. This could be done pharmacologically or by genetically targeting GS.”

Developing novel drugs that hinder tumor growth

The results of the pioneering study stress the importance of metabolic immunotherapy strategies in the fight against cancer.

Mazzone: “Our research proves that both the expression and the activity of glutamine synthetase are markers of malignant macrophages in tumors, and that blocking GS alters the cells’ metabolism in a way that may help hinder cancer growth. This generates exciting possibilities for the development of specific drugs. The VIB Discovery Sciences team has already established a screening assay to identify GS inhibitors which can serve as a starting point towards development of specific and potent GS drugs.”

Reference

Pharmacologic or genetic targeting of glutamine synthetase skews macrophages towards an M1-like phenotype and inhibits tumor metastasis, M. Palmieri et al., Cell Reports 2017

Read more about: , .

RELATED ARTICLES
Cancer immunotherapy: the ultimate ally in the tumor war

Can immunotherapy cure cancer? Fighting cancer with our own immune system. It sounds promising. At the end of the 1800s, the controversial Dr. Wil…


Engineered immune cells to fight cancer

Our own immune T-cells can be one of the best defense lines against cancer. Walloon biopharmaceutical company Celyad is using an innovative approa…


Damya Laoui at the forefront of cancer immunotherapy

Photo copyright: VUB / Thierry Geenen Last year, Damya Laoui received the prestigious American MIT-prize for young innovators under 35 for her…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven Biowin Turnstone Itera Life Science UGent Flanders.bio XpandInnovation V-Bio Ventures Janssen GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.